Stay updated with breaking news from Laurus Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ImmunoACT has portfolio of Chimeric Antigen Receptor T cells (CAR-T cells) therapy assets under various development stages for the treatment of multiple auto immune diseases and oncology indications.
Post the completion of the deal, Laurus Labs’ stake in ImmunoACT will increase to 33.86% on fully diluted basis.
Based on the OI percentage, 56 stocks were on the short-covering list. These included Balkrishna Industries, Divis Laboratories, Dabur India, Nestle India, and Britannia Industries.
Laurus Labs Ltd announced today that it has signed definitive agreements to acquire additional stake of 7.24% in Immunoadoptive Cell Therapy Private Limited.
Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 340 in its research report dated April 27, 2023.